Notably, among the 32 targets shared between 3xTg-AD and Neuro2a networks, 5 have previously been experimentally validated37, including hbegf, kdm5a, mapk1, mapt, and sirt1 (Fig. 2d). This evidence concerns the gene MAPT and Alzheimer disease.